Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BHVN
BHVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BHVN News
Biohaven Shares Enter Oversold Territory
6d ago
NASDAQ.COM
Sarissa Capital Management Acquires Stake in Biohaven Ltd.
Mar 23 2026
Fool
Sarissa Capital Management Increases Stake in Biohaven
Mar 23 2026
NASDAQ.COM
DAFNA Capital Management Increases Biohaven Stake
Mar 22 2026
NASDAQ.COM
DAFNA Capital Increases Biohaven Stake by 720,000 Shares
Mar 22 2026
Fool
Biohaven Completes Enrollment in Obesity Treatment Clinical Trial
Mar 19 2026
PRnewswire
Biohaven Completes Enrollment in Obesity Treatment Study
Mar 19 2026
Newsfilter
Xenon Plans New Drug Application Submission
Mar 10 2026
stocktwits
Biohaven Shares Fluctuate Following Positive Study Data
Mar 09 2026
Benzinga
Biohaven Reports Q4 Non-GAAP EPS Beat Expectations
Mar 02 2026
seekingalpha
Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies
Jan 21 2026
Benzinga
RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside
Jan 21 2026
CNBC
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data
Jan 15 2026
Benzinga
Biohaven Highlights Portfolio Progress at 44th Annual J.P. Morgan Healthcare Conference
Jan 12 2026
PRnewswire
Biohaven Reports Positive Clinical Results for TRAP Degrader in IgA Nephropathy Patients
Jan 12 2026
Newsfilter
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 07 2026
PRnewswire
Show More News
